|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-1-26
|
|
pubmed:abstractText |
A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Baclofen,
http://linkedlifedata.com/resource/pubmed/chemical/Glyceraldehyde-3-Phosphate...,
http://linkedlifedata.com/resource/pubmed/chemical/HD protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Monoamine Oxidase,
http://linkedlifedata.com/resource/pubmed/chemical/Monoamine Oxidase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Nerve Tissue Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Selegiline
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0885-3185
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 Movement Disorder Society
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
107-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14743370-Adolescent,
pubmed-meshheading:14743370-Adult,
pubmed-meshheading:14743370-Anemia, Hemolytic, Congenital,
pubmed-meshheading:14743370-Antiparkinson Agents,
pubmed-meshheading:14743370-Baclofen,
pubmed-meshheading:14743370-Basal Ganglia,
pubmed-meshheading:14743370-Basal Ganglia Diseases,
pubmed-meshheading:14743370-Blood Platelets,
pubmed-meshheading:14743370-Drug Therapy, Combination,
pubmed-meshheading:14743370-Dyskinesia, Drug-Induced,
pubmed-meshheading:14743370-Dystonia Musculorum Deformans,
pubmed-meshheading:14743370-Female,
pubmed-meshheading:14743370-Genotype,
pubmed-meshheading:14743370-Glyceraldehyde-3-Phosphate Dehydrogenases,
pubmed-meshheading:14743370-Heterozygote Detection,
pubmed-meshheading:14743370-Humans,
pubmed-meshheading:14743370-Long-Term Care,
pubmed-meshheading:14743370-Male,
pubmed-meshheading:14743370-Middle Aged,
pubmed-meshheading:14743370-Monoamine Oxidase,
pubmed-meshheading:14743370-Monoamine Oxidase Inhibitors,
pubmed-meshheading:14743370-Nerve Tissue Proteins,
pubmed-meshheading:14743370-Neurologic Examination,
pubmed-meshheading:14743370-Neuroprotective Agents,
pubmed-meshheading:14743370-Nuclear Proteins,
pubmed-meshheading:14743370-Polymerase Chain Reaction,
pubmed-meshheading:14743370-Proteins,
pubmed-meshheading:14743370-Psychoses, Substance-Induced,
pubmed-meshheading:14743370-Reference Values,
pubmed-meshheading:14743370-Selegiline,
pubmed-meshheading:14743370-Trinucleotide Repeats
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Adverse effects of dopamine potentiation by long-term treatment with selegiline.
|
|
pubmed:affiliation |
Department of Cell Biology, National Blood Transfusion Service, Budapest, Hungary. hollan@ella.hu
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
